Review
Copyright ©The Author(s) 2024.
World J Exp Med. Jun 20, 2024; 14(2): 93689
Published online Jun 20, 2024. doi: 10.5493/wjem.v14.i2.93689
Figure 1
Figure 1 The pathobiology of male obesity-related secondary hypogonadism. E: Estradiol; GnRH: Gonadotropin-releasing hormone; LH: Luteinizing hormone; T: Testosterone.
Figure 2
Figure 2 Therapeutic benefits of androgen replacement therapy in male obesity-related secondary hypogonadism. CV: Cardiovascular; SBP: Systolic blood pressure.